Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • RFK Jr.’s Future
  • Melanoma Drug
  • Charity Care Gap
  • Search for New FDA Chief

WHAT'S NEW

  • RFK Jr.'s Future
  • Melanoma Drug
  • Charity Care Gap
  • Search for New FDA Chief

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Dec 13 2021

Full Issue

4 In 10 Covid Infections In London Are Omicron As UK Reports First Death

The spread of omicron in the U.K. has reached "phenomenal" levels in London, and the Health Secretary was reported saying that new school shutdowns couldn't be ruled out. Separately, a study says poor mental health was the U.K.'s leading reason behind sick days in 2021.

Reuters: First Person Dies From Omicron Variant In United Kingdom

At least one person has died in the United Kingdom after contracting the Omicron variant of the coronavirus, Prime Minister Boris Johnson said on Monday, warning that the variant now accounted for 40% of infections in the British capital. Since the first Omicron cases were detected on Nov. 27 in the United Kingdom, Johnson has imposed tougher restrictions and on Sunday he urged people to get booster shots to prevent the health service from being overwhelmed. (McKay and Faulconbridge, 12/13)

Bloomberg: U.K. Says Can’t Rule Out Shutting Schools As Omicron Spreads

U.K. Health Secretary Sajid Javid said there’s no certainty the government will be able to keep schools in England open, as the government battles to contain the spread of the omicron Covid-19 variant. “When it comes to our fight against the pandemic there are no guarantees,” Javid told LBC radio on Monday, as he detailed plans to offer all adults in England a booster vaccination by the end of December. “We are once again in a race between the vaccine and the virus.” (Donaldson, 12/13)

Bloomberg: Working From Home Is Back: Mental Health Problems Cause Most U.K. Sick Leave

Poor mental health was the leading cause of British workers taking off work for illness in 2021, costing employers an estimated 43 billion pounds ($56.9 billion). That’s according to data from GoodShape, which manages workplace absences for companies and has a database of 750,000 employee records. GoodShape estimated that the cost of sick leave to employers rose by 31% from before the pandemic, not accounting for the cost of hiring and training replacement staff. Mental ill health accounted for 19% of all lost working time in the U.K. up to Nov. 28, slightly more than confirmed cases of Covid-19. That was the case across every industry except transport and logistics, consumer and retail, and workplace services. (Burden, 12/13)

In other global covid news —

NBC News: New U.S. Covid Travel Warnings Hit European Hot Spots

U.S. travel warnings are hitting longtime American tourist hot spots where it hurts, with some who depend on the dollar describing their situation as desperate. The Centers for Disease Control and Prevention this week advised Americans to avoid traveling to France, Portugal and several other European destinations, as well as to Jordan and Tanzania, citing concern over high rates of Covid-19. These destinations now join more than 70 other countries on the “Level 4: Very High” list, which also includes Germany, the United Kingdom and Denmark. (Elbaum and Ing, 12/9)

CNN: China Vaccines: Why The Government Is Reluctant To Approve Western MRNA Shots 

When the highly infectious Delta variant hit China in the summer, some public health experts were hopeful that the country could soon receive an immunity boost from BioNTech's highly effective mRNA Covid-19 vaccine. In July, the shot was reported to have passed an expert review by Chinese regulators and was in the administration review stage, according to Fosun Pharma, the Chinese partner of BioNTech licensed to produce and distribute the vaccine in the Greater China region. Fosun was even planning to start domestic trial production by the end of August. However, five months later there is still no word from Chinese officials on when -- or whether -- the vaccine will ever be approved, even as the newly emerged Omicron variant poses a fresh challenge to China's zero-Covid strategy -- and its less effective domestic vaccines. (Gan and George, 12/13)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 15
  • Thursday, May 14
  • Wednesday, May 13
  • Tuesday, May 12
  • Monday, May 11
  • Friday, May 8
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF